Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
academic research
Research
Turkish bank invests $39M in Harvard next-gen obesity antibodies
Once the antibodies are ready, a new biotech called Enlila will launch and may license them for clinical development.
Darren Incorvaia
Jun 16, 2025 1:07pm
Senators grill NIH chief over proposed $18B cut
Jun 10, 2025 5:21pm
OSE to lead mRNA project with €1.3M from French government
May 21, 2025 4:26pm
Scientists ID target to prevent cancer from spreading to bones
May 21, 2025 2:00pm
Trump admin cuts $450M more from Harvard funding
May 13, 2025 1:33pm
Trump aims to block pathogen research, citing ‘lab leak’ theory
May 6, 2025 9:05pm